@Shellbell where are you ? hoping your well and not too stressed out with proceedings here
Beyond stressed, mate, with the (perceived lack of) proceedings here and elsewhere! What Dingo has stated rings so true!
Whilst its understandable that certain segments of our "diversified pipeline" have been put on the back burner to conserve dollars, to optimise, and even possibly "buy time to assess the evolving landscape"... IMO, it could have been better handled. OmniCAR obviously required more preclinical R&D than was ever made out to be the case and yet we have not heard a peep on that front since. To turn off the marketing and SH engagement in the manner that he has only serves to highlight just how OTT it was 2 years ago when retail investment was at its peak.
Anyway, it is what it is and, at least, PTX-100 progressed to achieve successful Phase 1B results and we await news on the next step on the front. CellPryme is supposedly in 3rd party testing stages.... understandably nothing but the sound of crickets until something transpires to break the silence. It's simply a painful waiting game.
